文献速递消化系统肿瘤

高危个体胰腺癌监测与生存

Pancreatic Cancer Surveillance and Survival of High-Risk Individuals.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项比较队列研究在美国多个学术医学中心的高危个体胰腺癌监测项目中进行,比较26例监测发现胰腺导管腺癌的高危个体与1504例SEER匹配对照的生存。高危个体肿瘤更小、分期更低,5年胰腺癌死亡率43% vs 86%,中位总生存61.7个月 vs 8.0个月。作者认为监测可能有助于发现更小、更低分期的胰腺导管腺癌并改善生存。

要点

  • 高危个体监测发现的胰腺导管腺癌原发肿瘤中位直径2.5 cm,小于SEER对照的3.6 cm(P < .001)。
  • 高危个体Ⅰ期占38.5%、Ⅱ期占30.8%,SEER对照Ⅰ期占10.3%、Ⅱ期占25.1%(P < .001)。
  • 高危个体5年胰腺癌死亡率43% vs SEER对照86%,中位总生存61.7个月 vs 8.0个月。

核心结论

  • 这些发现提示,对高危个体进行监测可能发现更小、更低分期的胰腺导管腺癌并改善生存。

研究设计与样本

  • 这是一项在美国多个学术医学中心进行的比较队列研究,数据来自参与胰腺癌筛查项目的高危个体,该项目对具有家族性或遗传易感性的高危个体进行筛查。
  • 共纳入26例监测发现胰腺导管腺癌的高危个体,诊断时平均(标准差)年龄65.8(9.5)岁,女性15例(57.7%)。
  • 对照为从监测、流行病学和最终结果(SEER)项目中按年龄、性别和诊断年份匹配的1504例胰腺导管腺癌患者,诊断时平均(标准差)年龄66.8(7.9)岁,女性771例(51.3%)。
  • 胰腺癌筛查项目始于1998年,数据收集至2021年;数据分析于2022年4月29日至2023年4月10日进行。
  • 暴露为每年进行的内镜超声或磁共振成像以及标准治疗的 Surgery 和/或肿瘤内科治疗。

主要发现

  • 26例高危个体的原发肿瘤中位直径为2.5 cm(范围0.6-5.0),SEER对照为3.6 cm(范围0.2-8.0),P < .001。
  • 高危个体诊断时分期更低:Ⅰ期10例(38.5%)、Ⅱ期8例(30.8%);匹配对照Ⅰ期155例(10.3%)、Ⅱ期377例(25.1%),P < .001。
  • 高危个体5年胰腺癌死亡率低于对照(43% vs 86%;风险比3.58;95% CI,2.01-6.39;P < .001)。
  • 高危个体中位总生存长于匹配对照(61.7个月[范围1.9-147.3] vs 8.0个月[范围1.0-131.0]);5年总生存率50%(95% CI,32%-80%)vs 9%(95% CI,7%-11%)。

关键数值与推荐

  • 高危个体原发肿瘤中位直径2.5 cm(范围0.6-5.0)vs SEER对照3.6 cm(范围0.2-8.0),P < .001。
  • 高危个体Ⅰ期10例(38.5%)、Ⅱ期8例(30.8%)vs 匹配对照Ⅰ期155例(10.3%)、Ⅱ期377例(25.1%),P < .001。
  • 5年胰腺癌死亡率高危个体43% vs 对照86%,风险比3.58(95% CI,2.01-6.39),P < .001。
  • 中位总生存高危个体61.7个月(范围1.9-147.3)vs 匹配对照8.0个月(范围1.0-131.0)。
  • 5年总生存率高危个体50%(95% CI,32%-80%)vs 匹配对照9%(95% CI,7%-11%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with increasing incidence. The majority of PDACs are incurable at presentation, but population-based screening is not recommended. Surveillance of high-risk individuals for PDAC may lead to early detection, but the survival benefit is unproven. OBJECTIVE: To compare the survival of patients with surveillance-detected PDAC with US national data. DESIGN, SETTING, AND PARTICIPANTS: This comparative cohort study was conducted in multiple US academic medical centers participating in the Cancer of the Pancreas Screening program, which screens high-risk individuals with a familial or genetic predisposition for PDAC. The comparison cohort comprised patients with PDAC matched for age, sex, and year of diagnosis from the Surveillance, Epidemiology, and End Results (SEER) program. The Cancer of the Pancreas Screening program originated in 1998, and data collection was done through 2021. The data analysis was performed from April 29, 2022, through April 10, 2023. EXPOSURES: Endoscopic ultrasonography or magnetic resonance imaging performed annually and standard-of-care surgical and/or oncologic treatment. MAIN OUTCOMES AND MEASURES: Stage of PDAC at diagnosis, overall survival (OS), and PDAC mortality were compared using descriptive statistics and conditional logistic regression, Cox proportional hazards regression, and competing risk regression models. Sensitivity analyses and adjustment for lead-time bias were also conducted. RESULTS: A total of 26 high-risk individuals (mean [SD] age at diagnosis, 65.8 [9.5] years; 15 female [57.7%]) with PDAC were compared with 1504 SEER control patients with PDAC (mean [SD] age at diagnosis, 66.8 [7.9] years; 771 female [51.3%]). The median primary tumor diameter of the 26 high-risk individuals was smaller than in the control patients (2.5 [range, 0.6-5.0] vs 3.6 [range, 0.2-8.0] cm, respectively; P < .001). The high-risk individuals were more likely to be diagnosed with a lower stage (stage I, 10 [38.5%]; stage II, 8 [30.8%]) than matched control patients (stage I, 155 [10.3%]; stage II, 377 [25.1%]; P < .001). The PDAC mortality rate at 5 years was lower for high-risk individuals than control patients (43% vs 86%; hazard ratio, 3.58; 95% CI, 2.01-6.39; P < .001), and high-risk individuals lived longer than matched control patients (median OS, 61.7 [range, 1.9-147.3] vs 8.0 [range, 1.0-131.0] months; 5-year OS rate, 50% [95% CI, 32%-80%] vs 9% [95% CI, 7%-11%]). CONCLUSIONS AND RELEVANCE: These findings suggest that surveillance of high-risk individuals may lead to detection of smaller, lower-stage PDACs and improved survival.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Blackford AL, Canto MI, Dbouk M, et al. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. JAMA Oncol. 2024. PMID: 38959011. doi:10.1001/jamaoncol.2024.1930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。